-
Review
-
Korean J Med. 2006;71(1):274-274.
- Effect of Triple antiplatelet therapy with Low-dose cilostazol after DES Implantation
-
김준영&#;문승원&#;정종혁&#;김동한&#;양혁승&#;오영상&#;김수현&#;이상미&#;조장
-
.
- Effect of Triple antiplatelet therapy with Low-dose cilostazol after DES Implantation
-
-
1Department of Internal Medicine, Hanyang University College of Medicine, Seoul; 2Department of Life Science, Postech Biotech Center, Pohang University of Science and Technology, Pohang, Korea
-
- Abstract
- Background : In the CREST trial, there was a significantly lower binary restenosis rate in the cilostazol-treated patients
compared with the placebo-treated patients after bare-metal stent implantation. But it is uncertain that this result will be
supported after drug-eluting stent(DES) implantation especially with long-term low-dose cilostazol. So, we performed a
prospective randomized study to evaluate the effectiveness of long-term triple therapy with low-dose cilostazol after DES
implantation. Methods : From June 2004 to January 2006, we assigned 109 patients(132 lesions) who had successful coronary
DES implantation to receive aspirin and clopidogrel(Group I, n=53) or aspirin, clopidogrel and low-dose cilostazol(50mg BID)
(Group II, n=56) for 6 months. The primary end point was in-segment restenosis at follow-up angiogram. The secondary end
point were late loss, major adverse cardiac event, stent thrombosis. Results : The baseline clinical and angiographic
characteristics were similar between two groups. Angiographic follow-up was completed in 74% of patients and there were no
difference in the in-segment restenosis rate and there were also no significant differences in the secondary end points(Table 1).
The target vessel revascularization rate was 3.6%. there was one case of non-cardiac origin death in group II. Conclusions :
In our study there was no addititive effect of triple therapy with low-dose cilostazol in DES era.
Keywords :
